Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmalink Enters Manufacturing Agreement for Nefecon®

Published: Thursday, November 01, 2012
Last Updated: Wednesday, October 31, 2012
Bookmark and Share
Company has entered into a contract with Patheon.

Pharmalink AB has announced that it has entered into a contract with Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry for the manufacturing of Nefecon®, Pharmalink’s lead product.

Nefecon is being developed as the first on label medication specifically aimed at addressing the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease.

The agreement covers the manufacturing of Nefecon and is an important step in progressing the product towards the market. No commercial terms were disclosed.

Johan Häggblad, Managing Director of Pharmalink, said: “Despite the increasing recognition of IgA nephropathy as a significant cause of morbidity and mortality, no specific medications have been developed and introduced to the market. In that context, our development programme for Nefecon is seen as one of the most significant in IgA nephropathy clinical research. We have already shown positive results in an open-labelled Phase II trial evaluating Nefecon’s safety and efficacy and, with Patheon we will be working with one of the pharmaceutical industry’s best respected manufacturers as Nefecon advances towards pivotal trials.”

Nefecon is an enteric formulation of a locally-acting and potent corticosteroid which down regulates the IgA nephropathy disease process in the kidney through suppression of the gastrointestinal immune system thus exploiting the pivotal role the gastrointestinal tract plays in the overall immune response.

The target group for Nefecon is the approximately 40% patients with the more aggressive form of the disease and who are at risk of developing end stage renal disease.

The ultimate aim is to provide an alternative to dialysis and transplantation. Pharmalink has received orphan drug designation by the US Food and Drug Administration (FDA) for Nefecon.

Nefecon was invented at Uppsala University (Sweden) and was acquired by Pharmalink in 2004.

Nefecon® is delivered using the proprietary TARGIT® drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gastrointestinal tract.

Pharmalink has an exclusive licence to Targit® technology for the development of Nefecon® from Archimedes Pharma.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmalink AB Strengthens Senior Management Team
Dr. Heather Cook appointed director of regulatory affairs and Marek Poszepczynski as director of business development.
Thursday, February 21, 2013
Pharmalink Initiates Phase IIb Trial with Nefecon®
Pharmalink expects to announce top line results in the first half of 2015.
Friday, December 21, 2012
Pharmalink AB Raises SEK 35 Million through Share Issue
New funds used to further advance Nefecon® and Busulipo™.
Friday, January 06, 2012
Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program
Pharmalink also acquires equipment and technologies from Archimedes Pharma to manufacture TARGIT capsules for Nefecon.
Wednesday, December 14, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Fat Cells That Amplify Nerve Signals in Response to Cold Also Affect Blood Sugar Metabolism
Researchers at UTSW have found that the protein connexin 43 forms cell-to-cell communication channels on the surface of emerging beige fat cells that amplify the signals from those few nerve fibers.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!